Literature DB >> 9989517

Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study.

S W Lee1, B A Fraass, L H Marsh, K Herbort, S S Gebarski, M K Martel, E H Radany, A S Lichter, H M Sandler.   

Abstract

PURPOSE: To analyze the failure patterns for patients with high-grade astrocytomas treated with high-dose conformal radiotherapy (CRT) using a quantitative technique to calculate the dose received by the CT- or MR-defined recurrence volume and to assess whether the final target volume margin used in the present dose escalation study requires redefinition before further escalation. METHODS AND MATERIALS: Between 4/89 and 10/95, 71 patients with high-grade supratentorial astrocytomas were entered in a phase I/II dose escalation study using 3-D treatment planning and conformal radiotherapy. All patients were treated to either 70 or 80 Gy in conventional daily fractions of 1.8-2.0 Gy. The clinical and planning target volumes (CTV, PTV) consisted of successively smaller volumes with the final PTV defined as the enhancing lesion plus 0.5 cm margin. As of 10/95, 47 patients have CT or MR evidence of disease recurrence/progression. Of the 47 patients, 36 scans obtained at the time of recurrence were entered into the 3-D radiation therapy treatment planning system. After definition of the recurrent tumor volumes, the recurrence scan dataset was registered with the pretreatment CT dataset so that the actual dose received by the recurrent tumor volumes during treatment could be accurately calculated and then analyzed dosimetrically using dose-volume histograms. Recurrences were divided into several categories: 1) "central," in which 95% or more of the recurrent tumor volume (Vrecur) was within D95, the region treated to high dose (95% of the prescription dose); 2) "in-field," in which 80% or more of Vrecur was within the D95 isodose surface; 3) "marginal," when between 20 and 80% of Vrecur was inside the D95 surface; 4) "outside," in which less than 20% of Vrecur was inside the D95 surface.
RESULTS: In 29 of 36 patients, a solitary lesion was seen on recurrence scans. Of the 29 solitary recurrences, 26 were central, 3 were marginal, and none were outside. Multiple recurrent lesions were seen in seven patients: three patients had multiple central and/or in-field lesions only, three patients had central and/or in-field lesions with additional small marginal or outside lesions, and one patent had 6 outside and one central lesion. Since total recurrence volume was used in the final analysis, 6 of the 7 patients with multiple recurrent lesions were classified into centra/in-field category.
CONCLUSION: Analysis of the 36 evaluable patients has shown that 32 of 36 patients (89%) failed with central or in-field recurrences, 3/36 (8%) had a significant marginal component to the recurrence, whereas only 1/36 (3%) could be clearly labeled as failing mainly outside the high-dose region. Seven patients had multiple recurrences, but only 1 of 7 had large-volume recurrences outside the high-dose region. This study shows that the great majority of patient recurrences that occur after high-dose (70 or 80 Gy) conformal irradiation are centrally located: only 1/36 patients (with 7 recurrent lesions) had more than 50% of the recurrence volume outside the region previously treated to high dose. Further dose escalation to 90 Gy (and beyond) thus seems reasonable, based on the same target volume definition criteria

Entities:  

Mesh:

Year:  1999        PMID: 9989517     DOI: 10.1016/s0360-3016(98)00266-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  96 in total

1.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.

Authors:  Xintao Hu; Kelvin K Wong; Geoffrey S Young; Lei Guo; Stephen T Wong
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

2.  Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.

Authors:  Christina I Tsien; Doris Brown; Daniel Normolle; Matthew Schipper; Morand Piert; Larry Junck; Jason Heth; Diana Gomez-Hassan; Randall K Ten Haken; Thomas Chenevert; Yue Cao; Theodore Lawrence
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

3.  Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.

Authors:  Ilwoo Park; Gregory Tamai; Michael C Lee; Cynthia F Chuang; Susan M Chang; Mitchel S Berger; Sarah J Nelson; Andrea Pirzkall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-21       Impact factor: 7.038

Review 4.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

5.  Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults.

Authors:  John Buatti; Timothy C Ryken; Mark C Smith; Penny Sneed; John H Suh; Minesh Mehta; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

6.  Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patient.

Authors:  David E Gerber; Stuart A Grossman; Timothy A Chan; Lawrence Kleinberg
Journal:  J Radiother Pract       Date:  2007

7.  Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide.

Authors:  J Sherriff; J Tamangani; L Senthil; G Cruickshank; D Spooner; B Jones; C Brookes; P Sanghera
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

8.  Outcome of Adult Brain Tumor Consortium (ABTC) prospective dose-finding trials of I-125 balloon brachytherapy in high-grade gliomas: challenges in clinical trial design and technology development when MRI treatment effect and recurrence appear similar.

Authors:  L R Kleinberg; V Stieber; T Mikkelsen; K Judy; J Weingart; G Barnett; J Olson; S Desideri; X Ye; S Grossman
Journal:  J Radiat Oncol       Date:  2015-08-05

9.  A case of symptomatic synchronous cervical and cerebellar metastasis after resection of thoracal metastasis from temporal glioblastoma multiforme without any local recurrence.

Authors:  Yasar Karatas; Sahika Liva Cengiz; Mehmet Erkan Ustun
Journal:  Asian J Neurosurg       Date:  2016 Oct-Dec

10.  Radiosurgical boost for primary high-grade gliomas.

Authors:  Flavio E Prisco; Eduardo Weltman; Rodrigo M de Hanriot; Reynaldo A Brandt
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.